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ABSTRACT
Introduction: Progressive skeletal muscle wasting is the manifesting symptom of Duchenne muscular
dystrophy, an X-linked inherited disorder triggered by primary abnormalities in the DMD gene. The
almost complete loss of dystrophin isoform Dp427 causes a multi-system pathology that features in
addition to skeletal muscle weakness also late-onset cardio-respiratory deficiencies, impaired metabo-
lism and abnormalities in the central nervous system.
Areas covered: This review focuses on the mass spectrometry-based proteomic characterization of
X-linked muscular dystrophy with special emphasis on the identification of novel biomarker candidates
in skeletal muscle tissues, as well as non-muscle tissues and various biofluids. Individual sections focus
on molecular and cellular aspects of the pathogenic changes in dystrophinopathy, proteomic workflows
used in biomarker research, the proteomics of the dystrophin-glycoprotein complex and the potential
usefulness of newly identified protein markers involved in fibre degeneration, fibrosis and inflammation.
Expert opinion: The systematic application of large-scale proteomic surveys has identified a distinct cohort
of both tissue- and biofluid-associated protein species with considerable potential for improving diagnostic,
prognostic and therapy-monitoring procedures. Novel proteomic markers include components involved in
fibre contraction, cellular signalling, ion homeostasis, cellular stress response, energy metabolism and the
immune response, as well as maintenance of the cytoskeletal and extracellular matrix.
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1. Introduction
Progressive forms of inherited or acquired human disorders
that are associated with primary or secondary skeletal muscle
wasting are characterized by loss of contractile strength and
decreased adaptability to changed physical demands [1].
These neuromuscular symptoms can have a devastating
impact on the quality of life, especially muscular disorders of
early childhood [2]. In primary diseases of the skeletal muscu-
lature, functional deficiencies in contractile tissues are often
accompanied by alterations in cellular signalling mechanisms,
physiological homeostasis, energy metabolism and fibre type
distribution [3]. The most frequently inherited neuromuscular
disorder of early childhood is Duchenne muscular dystrophy,
which is associated with a substantial economic and caregiver
burden [4]. X-linked muscular dystrophy is a mono-genetic
disorder due to primary abnormalities in the largest human
gene, the Xp21-located and 79-exon spanning DMD gene [5].
This highly complex gene encodes proteins ranging from
approximately 71 to 427 kDa whereby the alternative usage
of seven promoters, which are linked to unique first exons, is
the basis of the tissue-specific production of a variety of dis-
tinct transcripts and corresponding protein products [6], as
outlined in Figure 1. The full-length Dp427-M isoform of dys-
trophin belongs to the class of giant muscle proteins, which
have been extensively characterized by biochemical and mass
spectrometric analyses [7].
Skeletal muscle dystrophin is located in the subsarcolemmal
cytoskeleton in voluntary contractile fibres and contains amino-
terminal and central actin-binding domains, multiple spectrin
repeats and a unique carboxy-terminal dystroglycan binding
domain [5]. The most progressive form of dystrophinopathy is
related to a great variety of patient-specific mutations, includ-
ing mostly large deletions or duplications, but also small dele-
tions, small insertions, splice site mutations, point mutations
and mid-intronic mutations [8]. These genetic abnormalities
result in the almost complete loss of the Dp427-M isoform
and cause a multi-system pathology that primarily affects the
skeletal musculature, but is also characterised by severe sec-
ondary dysfunctions in the cardio-respiratory system, the cen-
tral nervous system and metabolism, as well as accompanying
complications due to scoliosis [9]. Ideally, a panel of robust and
highly sensitive biomarkers would be available to evaluate the
various clinical features of dystrophinopathy and improve dif-
ferential diagnostic, prognostic and therapy-monitoring
procedures.
A variety of non-proteinaceous biomarker candidates of
muscular dystrophy, such as single nucleotide polymorphisms,
lipids, metabolites and extracellular microRNAs [10], as well as
skeletal muscle imaging technologies [11], have been evalu-
ated and shown considerable potential to improve diagnostics
[12]. Building on previous reviews on the usage of mass
spectrometric techniques in muscular dystrophy research
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[13–15], this article focuses on emerging proteomic biomar-
kers of X-linked muscular dystrophy. General background
information is based on established publications on the dys-
trophin-glycoprotein complex and muscular dystrophy.
Literature screening was carried out with the Pubmed data-
base and focused on mass spectrometry-based proteomic
studies using combinations of a variety of search terms, i.e.
‘proteomics‘, ‘mass spectrometry’, ‘Duchenne muscular
dystrophy’, ‘dystrophinopathy’, ‘dystrophin’, ‘dystrophin-
glycoprotein complex’, ‘diagnosis’ ‘prognosis’ ‘therapy’ and
‘biomarker’. Publications were then further screened for their
suitability based on the specific topic of this review, taking
into account the suggested total number of references.
Major findings on novel proteomic biomarker candidates
associated with skeletal muscle tissues, non-skeletal muscle
tissues and various biofluids and their potential relevance to
improve molecular diagnostics are discussed in individual sec-
tions. Illustrative figures are presented to summarize the com-
plex pathology of X-linked muscular dystrophy, the
bioanalytical workflow for the identification of novel disease
markers using mass spectrometry, the proteomic characteriza-
tion of the wider dystrophin-associated protein complex and
the biochemical diversity of recently identified proteomic bio-
marker candidates of chronic fibre degeneration, reactive
myofibrosis and sterile inflammation. A summary of the main
findings from proteomic studies that have focused on the
identification of the dystrophin complex and biomarker dis-
covery in dystrophic skeletal muscles, secondarily affected
non-skeletal muscle tissues and biological fluids are listed in
individual tables. A certain degree of overlap exists between
these listings due to the fact that some proteomic investiga-
tions have been concerned with both the basic biochemical
characterization of dystrophin complexes and the comparative
analysis of dystrophic tissues.
Figure 1. Schematic presentation of the DMD gene with tissue-specific promoters and domain structure of dystrophin protein isoforms. Shown is the overall
organization of the dystrophin gene, which represents the largest gene in the human genome and contains 7 different promoters for the tissue-specific expression
of full-length dystrophin isoforms Dp427-B (brain), Dp427-M (muscle) and Dp427-P (Purkinje cells), as well as the shorter dystrophin isoforms Dp260-R (retina),
Dp140-B/K (brain/kidney), Dp116-S (Schwann cells in peripheral nerves) and Dp71-G (ubiquitous). The dystrophin protein products are characterized by a highly
complex domain structure within tissue-specific protein isoforms. The diagram provides information on Dp427-associated domains for direct interactions with
dystrophin-binding proteins, such as β-dystroglycan (β-DG), neuronal nitric oxide synthase (nNOS), syntrophins (SYN) and dystrobrevins (DYB). Indirectly associated
proteins belonging to the core dystrophin-glycoprotein complex are also marked, including α-dystroglycan (α-DG), sarcoglycans (SG), sarcospan (SSPN), laminin and
cortical actin.
Article Highlights
● Duchenne muscular dystrophy is a highly complex multi-system
disorder that is characterized by chronic skeletal muscle wasting
● Mass spectrometry-based proteomics has identified new biomarker
candidates of dystrophinopathy
● Novel proteomic biomarkers include tissue-associated proteins
involved in a large variety of cellular processes.
● New biofluid-associated biomarkers have a great potential for
establishing superior diagnostic methods in the field of muscular
dystrophy.
● Promising new biomarker candidates include titin fragments in urine
and a variety of increased muscle proteins in serum, such as fibro-
nectin, carbonic anhydrase, myosin light chain, haptoglobin, fatty
acid binding proteins, myomesin and troponin.
● Newly identified biomarkers of muscular dystrophy have now to be
established in clinical laboratory practice
● Robust biomarkers may then be useful for the improved evaluation of
new treatment approaches, such as stem cell transfer or gene ther-
apy.
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2. Biomarker discovery for the molecular evaluation
of muscular dystrophy
Since only supportive treatments are available to address the
devastating effects of progressive muscle degeneration and
associated impairments of cardio-respiratory and cognitive
functions in X-linked muscular dystrophy, there is an urgent
need to improve diagnostic and prognostic methods to better
evaluate novel therapeutic approaches to counter-act chronic
muscle fibre wasting. Figure 2 summarizes the multi-system
disease process of dystrophinopathy and the affected tissues,
organs and biofluids, as well as the concept of tissue versus
liquid biopsy markers that may be useful for diagnostic pur-
poses. Dystrophic changes in the skeletal musculature are
highly complex and include progressive fibre degeneration,
reactive myofibrosis and sterile inflammation [16–18]. Cellular
features of dystrophic muscles include increased fibre branch-
ing, more rounded cellular shapes, altered myofibre size, cen-
tral nucleation due to degeneration-regeneration cycles,
necrosis and fatty deposition.
Importantly, the immune response that usually supports
repair mechanisms in acutely damaged skeletal muscle
tissue was shown to be aberrant in the context of chronic
muscle wasting. This involves both amplification of the
innate immune system and activation of the acquired
immune response, as extensively reviewed by Tidball
et al. [18]. A perturbed crosstalk between the immune
system and damaged muscles appear to amplify the dys-
trophic phenotype due to altered signalling patterns by
immuno-modulators. Some of the most prevalent cell
types of the innate immune response are present during
the initial non-specific inflammatory response, including
macrophages, neutrophil granulocytes and mast cells.
However, more specific reactions also occur and are
mediated by eosinophils, as well as key cells of the adap-
tive immune response such as cytotoxic CD8
+ T-lymphocytes. This dysregulation of the immune
response in association with chronic fibre injury is involved
in promoting profibrotic changes that eventually cause
severe myofibrosis [19]. Importantly, a longitudinal and
multi-parametric analysis of fibrotic changes in dystrophic
muscles highlighted the fact that endomysial fibrosis is the
only significant myopathological characteristic that reliably
correlates with the weakening of contractile strength [20].
Hence, the excessive accumulation of collagen and asso-
ciated components of the extracellular matrix appears to
be directly involved in the gradual decline in skeletal mus-
cle elasticity and reduced motor functions in X-linked mus-
cular dystrophy [21].
A major goal of current proteomic studies of muscular dys-
trophy is to identify novel protein biomarkers that are charac-
teristic for individual aspects of the diverse pathobiochemical
changes observed in dystrophinopathy. In general, biomarker
types can be divided into (i) susceptibility markers that are
Figure 2. Overview of the multi-system disease process of Duchenne muscular dystrophy. Shown are the affected tissues, organs and biofluid systems, as well as the
concept of tissue versus liquid biopsy biomarkers that may be useful for diagnostic, prognostic and therapy-monitoring purposes.
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useful to estimate the risk for disease initiation in otherwise
healthy individuals, (ii) diagnostic markers for the initial differ-
ential and reliable detection of a specific disease process, (iii)
prognostic markers that can be useful for envisaging disease
progression and adverse clinical events, (iv) predictive markers
that are capable for differential patient screening and their
individual sensitivity towards therapeutic interventions, (v)
pharmacodynamic markers that reflect the response of the
body to a specific treatment, (vi) therapy-monitoring markers
that are suitable for the repeated assessment of potential
changes in pathological status due to therapy, and (vii) safety-
related biomarkers that are capable of measuring cytotoxic side
effects in association with aggressive treatments [12]. The avail-
ability of robust biomarker signatures is especially crucial for the
evaluation of new experimental treatments.
Previous pharmacological trials have focused on modulat-
ing calcium homeostasis, cellular growth, energy metabolism,
the immune response, inflammation, oxidative stress and
blood flow. Currently the feasibility of various innovative ther-
apeutic approaches is tested in preclinical or clinical trials.
These new methodologies include stem cell therapy, myoblast
transfer, utrophin substitution therapy, enhancement of the
cellular stress response, transcutaneous electrical nerve stimu-
lation and improved steroid therapy, as well as a variety of
direct or indirect genetic approaches including plasmid
transfer, viral transfer, naked DNA transfer, mini-dystrophin
delivery, stop codon read-through therapy, exon-skipping
therapy and CRISPR/Cas9-based partial genome editing [22–
24]. Potentially dangerous side effects due to de novo dystro-
phin expression following gene therapy were recently high-
lighted by the immunological evaluation of exon skipping in
the mdx mouse [25]. Newly synthesised dystrophin molecules
were shown to trigger both cell-mediated and humoral
immune responses, which suggests that exon skipping ther-
apy might be complicated by a long-term autoimmune
response and associated cellular damage [25].
In general, the detailed biomedical value and associated
complications of these types of new therapies are not easily
measured. Findings from clinical strength tests, which are
partially based on psychological motivation, can be mislead-
ing. Routine testing of serum enzymes, such as creatine kinase
or other general markers of muscle damage, are not specific
enough for the reliable evaluation of a specific neuromuscular
disorder, such as X-linked muscular dystrophy. To overcome
this shortage of suitable disease markers, comparative proteo-
mics suggests itself as an ideal screening tool for the high-
throughput comparison of normal versus dystrophic samples.
The flow diagram in Figure 3 outlines the general bioanalytical
workflow used in the standardized mass spectrometry-based
proteomic identification of novel biomarker candidates.
Figure 3. Bioanalytical workflow of the mass spectrometry-based proteomic identification of novel biomarker candidates of X-linked muscular dystrophy. Shown is
a diagram that summarizes the various bioanalytical steps that are used for the routine evaluation of protein markers. Transverse cryosections of diaphragm muscle
from wild type (wt) versus the dystrophic mdx-4cv mouse model of dystrophinopathy show typical histopathological features of dystrophin-deficient skeletal muscle
fibres. Bar equals 50 μm.
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Patient specimens and cell culture models can be used to
study both skeletal muscle and non-muscle tissues, as well as
suitable biofluids. However, due to high levels of inter-
individual differences between patients and the extremely
restricted amounts of human tissue biopsy specimens that
are available for large-scale screening studies, most proteomic
studies of muscular dystrophy have initially been carried out
with samples from genetic animal models of this frequently
inherited human neuromuscular disorder [26]. The histological
and immunofluorescence microscopical analysis shown in
Figure 3 illustrates the suitability of the dystrophic mdx-4cv
strain, which arose from chemical mutagenesis [27], for pro-
teomic analyses. Transverse cryosections of the diaphragm
from this animal model show typical features of dystrophin-
deficient muscle fibres, such as differing fibre sizes, central
nucleation, sterile inflammation and reactive myofibrosis.
For proteomic analyses of dystrophic tissues, proteins are
routinely extracted from organs, tissues, cells, subcellular frac-
tions, isolated protein assemblies or biological fluids and then
separated by one-dimensional gel electrophoresis, two-
dimensional gel electrophoresis and/or liquid chromatography
[13–15]. Typical bottom-up proteomics is based on the enzy-
matic digestion of protein mixtures followed by peptide mass
spectrometry for the identification of individual protein spe-
cies. In contrast, top-down or middle-down proteomics usually
starts with isolated proteoforms that have been isolated to
homogeneity by biochemical purification methods or high-
resolution two-dimensional gel electrophoresis. Intact proteins
or large protein fragments are then treated in a similar way as
in bottom-up approaches for the characterization of their
peptide sequence and post-translational modifications. In
comparative proteomics, systems bioinformatics plays
a crucial role in the establishment of proteome-wide changes
in particular protein families, biochemical pathways, cellular
signalling cascades and protein interaction networks. The exis-
tence of large databanks of already catalogued and character-
ized skeletal muscle-associated proteins is extremely helpful
for more refined proteomic investigations [28–31]. Routine cell
biological, immunochemical and physiological assays are used
for the independent verification of proteomic findings and the
confirmation of new biomarker candidates. These tests often
include combinations of comparative immunoblotting,
enzyme-linked immunosorbent assays, immunofluorescence
microscopy, immunoprecipitation, biochemical binding assays,
physiological measurements and enzyme assays.
3. Proteomic profiling of muscular dystrophy
The proteomic analysis of cells, tissues and organs that are
directly or secondarily involved in the multi-system pathology
of dystrophinopathy has been carried out with a focus on the
characterization of (i) full-length dystrophin Dp427-M and
related isoforms, (ii) its tightly bound dystrophin-associated
glycoprotein complex, (iii) the wider dystrophin complexome
including components of the sarcolemma, intracellular cytos-
keletal networks and the extracellular matrix, (iv) subtypes of
dystrophic skeletal muscles with varying degrees of
progressive degeneration, including predominantly slow-
twitching versus faster twitching limb muscles, naturally pro-
tected extraocular muscles and highly fibrotic diaphragm mus-
cle and (v) non-skeletal muscle tissues, such as the heart, brain
and liver.
3.1. Proteomic characterization of skeletal muscle
dystrophin and the dystrophin-associated sarcolemmal
protein complex
The dystrophin-glycoprotein complex forms a trans-
sarcolemmal bridge between the intracellular cytoskeletal net-
work and the basal lamina component laminin and
its associated extracellular matrix, which is crucial for lateral
force transmission and stabilisation of the fibre periphery dur-
ing repeated excitation-contraction-relaxation cycles [32]. In
addition, the dystrophin complex functions as a molecular scaf-
fold for anchoring signalling proteins and plasmalemmal recep-
tors [33]. The proteomic profile of full-length dystrophin isoform
Dp427-M and its tightly bound dystrophin-associated core com-
plex, as well as the indirectly linked components that belong to
the laminin-dystroglycan-actin axis are shown in Figure 4. Both,
focused studies on the mass spectrometric identification and
biochemical characterization of the dystrophin-glycoprotein
complex, as well as systematic cataloguing studies of muscle
tissue and cell lines, have been carried out over the last decade.
A summary of major proteomic studies on dystrophin and the
dystrophin complexome is provided in Table 1 [28–30,34–45].
Building on the initial biochemical characterization of the
dystrophin complex by density gradient ultracentrifugation
and chemical crosslinking analysis [32,46,47], proteomic stu-
dies could confirm the close linkage of dystrophin with the
integral glycoprotein β-dystroglycan and its associated extra-
cellular laminin-binding protein α-dystroglycan [34,38–45].
Cortical actin, syntrophins, dystrobrevins, the α,β,γ,δ-
sarcoglycan complex and laminin subunits are routinely iden-
tified by mass spectrometric surveys [28–30]. However, the
integral protein sarcospan is often only identified by low
sequence coverage using peptide mass spectrometry, even
in highly enriched subcellular fractions from skeletal muscle
[45], which is probably due to its low abundance and highly
hydrophobic properties. Components of the wider dystrophin
complex include caveolin, the desmoglein/desmoplakin com-
plex, desmin, actinin, synemin, tubulins, vimentin and plectin
on the intracellular side, and various collagen isoforms, fibro-
nectin and biglycan on the extracellular side of muscle fibres
[38–44] (Figure 4).
3.2. Proteomic profiling of dystrophic skeletal muscles
The pathobiochemical complexity of the dystrophic pheno-
type, which is characterized by progressive fibre degeneration,
cycles of regeneration, fat substitution, reactive myofibrosis
and inflammation in the skeletal musculature, complicates
the interpretation of proteomic surveys. However, the usage
of subcellular fractionation procedures, biochemical enrich-
ment strategies, model systems from different animal species
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Figure 4. Proteomic profile of full-length dystrophin isoform Dp427-M and its tightly bound dystrophin core complex, as well as the indirectly associated
components that belong to the laminin-dystroglycan-actin axis. The proteomic fingerprint of individual proteins is symbolized by green bars [45].
Table 1. Mass spectrometric identification of dystrophin and its tightly associated protein complex. Listed are major proteomic studies with a focus on the mass
spectrometric characterization of dystrophin isoform Dp427-M and its closely associated sarcolemmal protein complex, as well as comprehensive cataloguing studies
of skeletal muscles that have identified the various members of the dystrophin-glycoprotein complex. Abbreviations used: DIGE, difference in-gel electrophoresis;
FASP, filter-aided sample preparation; IP, immunoprecipitation; LC-MS/MS, liquid chromatography tandem mass spectrometry; MALDI ToF, matrix assisted laser
desorption/ionization time-of-flight; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; WGA, wheat germ agglutinin; XL, chemical crosslinking.
Species/Tissue Methods Proteomic identification Reference
C2C12 cell line FASP, LC-MS/MS analysis of assessable
muscle cell proteome
Coverage of dystrophin complex in muscle protein
databank
[28]
Mouse soleus and extensor digitorum longus,
mechanically extracted fibres
FASP, off-gel fractionation, in-stage tip
method, LC-MS/MS of single fibres
Comprehensive coverage of the core dystrophin-
glycoprotein complex and associated protein species
[29]
Mouse diaphragm LC-MS/MS analysis of assessable
diaphragm proteome
Comprehensive coverage of dystrophin-glycoprotein
complex
[30]
Rabbit skeletal muscle SDS-PAGE, On-membrane digestion, LC-
MS/MS
Dystrophin Dp427-M, sarcoglycan subcomplex [34]
C2C12 myoblast lysate SDS-PAGE, LC-MS/MS MS-based mapping of dystrophin molecule [35]
Human muscle, SILAC mouse gastrocnemius SDS-PAGE, LC-MS/MS MS-based quantitation of dystrophin Dp427-M [36]
Human embryonic kidney 293T cells Expression of recombinant mouse α-DG,
MALDI-ToF MS
Glycopeptide profiling of α-dystroglycan [37]
Cardiac muscle from various mouse strains (mdx-
5cv, nNOS-KO); human cardiac biopsy
IP using antibodies to dystrophin, LC-
MS/MS
Differential proteomic profiling of heart versus muscle
dystrophin complex
[38]
Quadriceps and gastrocnemius muscles from
various mouse strains (mdx-23, Galgt2
transgenic)
IP using antibodies to β-dystroglycan,
LC-MS/MS
Coverage of dystrophin complex and identification of
new dystroglycan-associated proteins
[39]
Hind limb muscle from various mouse strains
(mdx-5cv, Dag1)
IP, WGA lectin-based precipitation; LC-
MS/MS
Identification of novel dystroglycan complexes in
skeletal muscle
[40]
Mouse and rabbit skeletal muscles Sucrose gradient ultracentrifugation, IP,
LC-MS/MS
Detailed proteomic analysis of the muscle dystrophin-
glycoprotein complex
[41]
Rabbit skeletal muscle and mouse quadriceps
femoris
Ultracentrifugation, SDS-PAGE, on-
membrane digestion, LC-MS/MS
Characterization of the core dystrophin complex and
co-purifying proteins
[42]
Rabbit skeletal muscle WGA lectin affinity purification, LC-MS
/MS
Subcellular localization of dystrophin-glycoprotein
complex
[43]
Mouse skeletal muscle IP, XL, LC-MS/MS Proteomic profiling of β-dystroglycan subcomplex [44]
Mouse hind limb muscle WGA lectin affinity agglutination of
sarcolemma, LC-MS/MS
Comprehensive profile of dystrophin complexome and
laminin-dystroglycan-actin axis
[45]
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and the comparative analysis of different subtypes of skeletal
muscles has helped in the establishment of differential effects
of dystrophin deficiency on individual skeletal muscles.
A listing of overlapping protein hits from individual proteomic
studies has recently been provided in a supplementary file of
a review on muscular dystrophy [15], but these tables have
excluded crucial information from gel-based proteomics. High-
resolution two-dimensional gel electrophoresis, especially in
combination with differential fluorescent tagging of entire
proteomes, is a highly effective way of analysing skeletal
muscle tissue [31]. Thus, for an updated and inclusive presen-
tation of promising proteomic markers, this article lists studies
that were conducted with both gel-based and gel-free meth-
odologies. This information could be extremely helpful for the
future testing and clinical establishment of novel and more
robust biomarkers of Duchenne muscular dystrophy.
Table 2 provides an overview of the diversity of protein
changes that have been identified by the systematic compar-
ison of various skeletal muscles using highly sensitive mass
spectrometric techniques [30,39–42,44,45,48–78]. As recently
reviewed [3], proteomic studies revealed that the dystrophin-
deficient skeletal musculature undergoes only moderate fibre
type shifting on the level of bioenergetic pathways and the
contractile apparatus. Although degenerative processes are
observed in fast-twitching type IIb fibres prior to slower
twitching fibre populations, and a considerable number of
fibres in Duchenne patients appear to contain mostly the
adult slow MyHC isoform of myosin heavy chain, proteomic
studies indicate only modest alterations in the overall sarco-
meric apparatus [14,15,17]. Table 2 lists the subtypes of skele-
tal muscles investigated in individual proteomic studies, and
therefore correlates types of muscle, such as fast versus slow
and glycolytic versus oxidative fibre populations, with key
proteome-wide changes. The table also lists the main techni-
ques used during proteomic surveys of specific skeletal mus-
cles and therefore puts the main proteomic findings reported
in a specific publication in the context of muscle subtypes.
The proteomic identification of new protein candidates
using gel-free versus gel-based approaches is usually confir-
matory or at least complementary in nature. Two-dimensional
gel electrophoresis has the advantage of separating specific
proteoforms by their unique combination of isoelectric point
and molecular mass [48–55,57–59,61,63,65,70,78]. This type of
top-down proteomics visualizes the actual protein species
prior to digestion and is thus especially useful for the compre-
hensive analysis of the various isoforms of the actin-myosin
apparatus and metabolic proteins. In contrast, integral mem-
brane proteins, very large protein species and molecules with
extreme isoelectric points are often underrepresented in 2D-
gel systems. These types of muscle proteins are more
appropriately analyzed by one-dimensional gel electrophore-
tic techniques that can be combined with on-membrane
digestion and mass spectrometry [34,43,72,77] or affinity pur-
ification and immunoprecipitation approaches [39,41,44,77].
Alternatively, skeletal muscle proteins that are present in
crude tissue extracts or subcellular fractions can be conveni-
ently analyzed by bottom-up proteomics, which employs
trypsination of total protein complements in combination
with liquid chromatography and mass spectrometry
[30,45,56,60,62,64,66–69,71,73–76,78].
The majority of comparative proteomic analyses of dys-
trophic skeletal muscle tissues has shown a greater number
of increased versus decreased protein species, which is prob-
ably due to the occurrence of degeneration/regeneration
cycle in the absence of dystrophin. Overlapping proteomic
hits suggest that a variety of skeletal muscle-associated pro-
teins are suitable candidates for the establishment of
a biomarker signature of X-linked muscular dystrophy. This
includes marker proteins involved in fibre contraction, energy
metabolism, cytoskeletal maintenance, the cellular stress
response and ion homeostasis (Table 2). The initial gel-based
proteomic screening of mdx-23 skeletal muscles identified
a decreased concentration of adenylate kinase isoform AK1
[48], which was confirmed by several studies using both two-
dimensional gel electrophoresis and liquid chromatography
[50–52,56,59]. Lower levels of adenylate kinase may be linked
to abnormal nucleotide metabolism in muscular dystrophy
[50]. Another striking characteristic of dystrophic fibres are
decreased levels of the cytosolic Ca2+-binding protein regucal-
cin [51,52] and the luminal Ca2+-sequestering proteins calse-
questrin of the terminal cisternae region and sarcalumenin of
the longitudinal tubules [45,49,61,64]. Changes in theses
abundant Ca2+-binding proteins were identified in both the
highly fibrotic diaphragm and less severely affected leg mus-
cles, indicating a general role in the molecular pathogenesis of
dystrophinopathy. The enhanced susceptibility of dystrophin-
lacking muscle fibres to micro-rupturing of the fragile sarco-
lemma causes an increased influx of Ca2+-ions, which in turn
results in higher levels of proteolytic degradation [16]. The
additional impairment of efficient Ca2+-buffering in the cytosol
and lumen of the sarcoplasmic reticulum appears to exacer-
bate these physiological disturbances of excitation-contraction
coupling in muscular dystrophy [49].
A very interesting biomarker candidate that has been
repeatedly identified by mass spectrometry in dystrophin-
deficient contractile tissues is the CA3 isoform of carbonic
anhydrase [51,53,57,59,69–71]. This metabolic enzyme cata-
lyses the reversible hydration of carbon dioxide to carbonic
acid. The CA3 isoform is present in all muscle fibre types
with the highest density in slow-twitching type 1 fibres.
Altered CA3 levels and its leakage into the circulatory sys-
tem may be related to fibre type-specific susceptibilities and
accompanying changes in the dystrophic phenotype [3].
Consistent changes were also reported for annexin isoforms
ANX1, ANX2 and ANX5, which may be related to disturbed
Ca2+-homeostasis and repair mechanisms within dystrophic
fibres [42,45,50,61,64,67,71–74]. Potential compensatory
mechanisms that are based on the up-regulation of cytos-
keletal elements were confirmed by mass spectrometry.
A drastically increased vimentin and desmin concentration
seems to be a reliable indicator of cytoskeletal restructuring
in Dp427-deficient fibres [51,52,54,55,57,58,63,66,67,77]. The
fact that high levels of cellular stress is associated with
muscular dystrophy was verified by the proteomic
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Table 2. Proteomic profiling of dystrophic skeletal muscle tissues. Listed are major proteomic studies with a focus on the comparative mass spectrometric analysis of
dystrophin-deficient skeletal muscle tissues. Abbreviations used: 2D-GE, two-dimensional gel electrophoresis; DIGE, difference in-gel electrophoresis; ICAT, isotope-
coded affinity tag; ICPL, isotope-coded protein labeling; IEF, isoelectric focusing; IP, immunoprecipitation; iTRAC, isobaric tag for relative and absolute quantitation;
LC-MS/MS, liquid chromatography tandem mass spectrometry; MALDI ToF, matrix assisted laser desorption/ionization time-of-flight; MudPIT, multidimensional
protein identification technology; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SILAM, stable isotope labeling in mammals; Stains-All,
cationic carbocyanine dye staining; TMT, tandem mass tag; XL, chemical crosslinking.
Species/Tissue Methods Key proteomic changes Reference
Mouse mdx-23 hind limb muscle 2D-GE, MALDI-ToF MS Decreased adenylate kinase AK1 [48]
Mouse mdx-23 hind limb muscle 2D-GE, MALDI-ToF MS, 2D Stains-All Decreased calsequestrin CSQ1 and sarcalumenin [49]
Mouse mdx-23 hind limb muscle (cytosol) 2D-GE, MALDI-ToF MS Increased creatine kinase, myosin light chain MLC2 and
annexin ANX5; decreased adenylate kinase AK1
[50]
Mouse mdx-23 diaphragm 2D-DIGE, MALDI-ToF Increased heat shock protein cvHSP, desmin and
vimentin; decreased adenylate kinase AK1, regucalcin,
carbonic anhydrase CA3
[51]
Mouse mdx-23 diaphragm 2D-GE, MALDI-ToF MS Increased vimentin, desmin, albumin; decreased
regucalcin, adenylate kinase AK1, alphaB-crystallin
[52]
Mouse mdx-23 and antisense PMO-treated
diaphragm
2D-DIGE, MALDI-ToF Reversal of expression changes in heat shock protein
cvHSP, adenylate kinase AK1 and carbonic anhydrase
CA3
[53]
Mouse mdx-23 extraocular muscle 2D-DIGE, LC-MS/MS Minimal changes; increased desmin [54]
Mouse mdx-23 gastrocnemius 2D-DIGE, MALDI-ToF MS Increased vimentin,
various heat shock proteins
[55]
Dog GRMD vastus lateralis ICAT, phosphoprotein enrichment,
LC-MS/MS
Increased phosphorylated tropomyosin-4; decrease in
PGC-1α regulated metabolic proteins
[56]
Mouse mdx-23 quadriceps and gastrocnemius IP using antibodies to β-
dystroglycan, LC-MS/MS
Increased levels of utrophin and ankyrin-1 in mdx-23
dystroglycan complexes
[39]
Mouse mdx-23 diaphragm 2D-DIGE, LC-MS/MS Increased desmin, vimentin; decreased adenylate kinase
AK1 and carbonic anhydrase CA3
[57]
Mouse mdx diaphragm 2D-GE, LC-MS/MS Increased collagen VI, dermatopontin, vimentin, alphaB-
crystallin; decreased myozenin-1
[58]
Mouse mdx-23 tibialis anterior 2D-GE, LC-MS/MS Increased carbonic anhydrase CA3 during mdx-23 aging [59]
Dog GRMD cranial sartorius LC-MS/MS Increased spectrin; decreased laminin-α2 [60]
Mouse mdx-23 diaphragm 2D-DIGE, LC-MS/MS Increased heat shock protein cvHSP, dermatopontin,
decreased parvalbumin, calsequestrin CSQ1, adenylate
kinase AK1, annexin ANX5
[61]
Mouse mdx-23 gastrocnemius SILAM mouse analysis, LC-MS/MS Complex changes in pathways related to kinases,
cytoskeleton, energy metabolism and calcium
homeostasis
[62]
Mouse mdx-23 soleus, extensor digitorum longus,
flexor digitorum brevis and interosseus
2D-DIGE, LC-MS/MS Differential protein changes in individual muscles;
increased alphaB-crystallin, vimentin, desmin;
decreased parvalbumin
[63]
Mouse mdx-23 diaphragm versus extraocular muscle TMT isobaric mass tagging, MudPIT,
LC-MS/MS
Differential expression levels; increased annexin ANX1
and ANX5, decreased calsequestrin CSQ1 in mdx
diaphragm
[64]
Mouse mdx-23 hind limb muscles (microsomes) 2D-GE, LC-MS/MS Increased heat shock protein Hsp70, transferrin, ferritin [65]
Mouse mdx-23 diaphgram LC-MS/MS Increased periostin, dermatopontin, desmin, obscurin and
vimentin
[66]
Mouse mdx-23 diaphragm, soleus, extensor digitorum
longus, flexor digitorum brevis and interosseus
LC-MS/MS Increased annexin ANX2 and ANX5, lamin A/C-B and
vimentin
[67]
Mouse mdx-23 and antisense PMO-treated tibialis
anterior
iTRAC, IEF, LC-MS/MS Partial restoration of mdx-23 proteome following exon
skipping, including dystrophin-associated proteins
[68]
Mouse mdx-4cv hind limb muscles (microsomes) LC-MS/MS Decrease in dystrophin complex, carbonic anhydrase CA3;
increased anti-trypsin, myoferlin and periostin
[69]
Mouse mdx-23 quadriceps following low-intensity
endurance exercise
2D-GE, MALDI-ToF MS Differential effect of exercise on carbonic anhydrase CA3
and superoxide dismutase SODC
[70]
Mouse mdx-4cv hind limb muscles LC-MS/MS Decrease in dystrophin complex, carbonic anhydrase CA3,
parvalbumin; increased collagens, fibronectin,
biglycan, dysferlin and annexins
[71]
Dog GRMD biceps femoris following allogenic
MuStem cell application
ICPL, SDS-PAGE, LC-MS/MS MuStem cell-induced additional increase in annexin ANX1
and ANX5, ferritin, haptoglobin
[72]
Mouse mdx-4cv gastrocnemius and C2C12 myoblasts LC-MS/MS Increased annexin ANX1 and ANX5, periostin, lumican,
albumin
[73]
Pig DMD biceps femoris LC-MS/MS Increased caveolin; decreased fast troponin TnC,
endoplasmin
[74]
Mouse mdx-23 skeletal muscles Sucrose gradient
ultracentrifugation, IP, LC-MS/MS
Disruption of the dystrophin-glycoprotein complex in
mutants
[41]
Mouse mdx-23 and mdx-52 gastrocnemius SILAM mouse analysis, LC-MS/MS Increased dysferlin, annexin ANX1 and ANX2; alterations
in mitochondrial proteins
[75]
Mouse mdx-23 quadriceps femoris Ultracentrifugation, SDS-PAGE, on-
membrane digestion, LC-MS/MS
Decreased desmoglein and FABP1; increased annexin
ANX1, biglycan and fibronectin
[42]
Mouse mdx-4cv skeletal muscles Lectin agglutination of sarcolemma,
LC-MS/MS
Increased integrin and neural cell adhesion molecule
NCAM1
[76]
(Continued )
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identification of a variety of molecular chaperones, includ-
ing the heat shock proteins cvHsp, αB-crystallin, Hsp70 and
Hsp90 [51,52,55,58,61,63,65].
Reactive myofibrosis is a histopathological hallmark of
X-linked muscular dystrophy and closely related to loss in
motor functions [17,19–21]. Proteomics established an
increased density of a variety of markers of the extracellular
matrix, such as collagens, dermatopontin, the matricellular
protein periostin, fibronectin, biglycan, lumican and asporin
[42,58,61,66,69,71,73]. Additional biomarker candidates of dys-
trophinopathy are represented by albumin, myosin light
chains, the actin binding-protein profilin, the lipid droplet-
associated protein perilipin and various glycolytic and mito-
chondrial enzymes [30,39–42,44,45,48–78]. Figure 5 gives an
overview of the wider dystrophin complexome of the muscle
fibre periphery and its association with the extracellular
matrix, the cytoskeletal network and the muscle membrane
system consisting of the sarcolemma, transverse tubules and
the sarcoplasmic reticulum, as revealed by proteomic studies
[39–45]. The concentration of a large number of these directly
or indirectly dystrophin-associated proteins is changed in dys-
trophic skeletal muscles and these pathobiochemical altera-
tions can now be used as proteome-wide evidence for
establishing a robust biomarker signature of dystrophinopathy
(Table 2).
3.3. Proteomic analysis of non-skeletal muscle tissues
Although dystrophinopathies are primarily classified as
muscle diseases with characteristic neuromuscular symp-
toms [5], Duchenne muscular dystrophy is a multi-system
disorder with severe complications due to cardiac failure,
respiratory dysfunction, scoliosis, impaired liver metabo-
lism, renal abnormalities and cognitive impairments [9].
Most studies into proteome-wide changes in non-skeletal
muscle tissues [79–86] have focused on preparations from
the dystrophin-deficient heart [38,79–81,84], but muscular
dystrophy-related effects on the brain [82,86], kidney [83]
and liver [85] have also been studied by proteomics.
Investigations using both gel-based and gel-free systems
have established changed concentration levels in protein
markers of energy metabolism, ion homeostasis, the extra-
cellular matrix and cytoskeletal networks. Table 3 lists pro-
teomic biomarker candidates from non-skeletal muscle
tissues that are significantly changed in X-linked muscular
dystrophy [79–86]. This includes cardiac-specific changes in
the core dystrophin complex, mitochondrial enzymes, the
basal lamina and associated extracellular matrix [38,79–
81,84], which might be linked to the cardio-respiratory
syndrome in X-linked muscular dystrophy [5].
An interesting finding in relation to hepatic alterations is
the identification of elevated levels of fatty acid binding pro-
tein FABP5 in the mdx-4cv liver. Dystrophinopathies appear to
be associated with secondary alterations that especially affect
fatty acid transportation in liver tissue [85]. A useful indicator
of potential side effects of exon skipping therapy on the
kidney was identified as the renal marker protein meprin
MEP-1 [83]. Since a subset of children suffering from X-linked
muscular dystrophy is also affected by neuropathological
complications that affect emotion, language, attention and
memory [5], it is of interest that the proteomic analysis of
the central nervous system from the mdx-4cv mouse model
has established an increased concentration of glial fibrillary
acid protein GFAP [82,86]. Since GFAP is an intermediate fila-
ment component of astrocytes in the brain, its elevated con-
centration implies neurodegeneration-associated astrogliosis
in muscular dystrophy. Thus, gliosis may be a contributing
factor that is involved in dystrophinopathy-related cognitive
impairments and brain abnormalities.
4. Targeted biomarker discovery in biofluids
In paediatric muscle disease diagnostics, the routine usage of
minimally- or non-invasive methods is usually advantageous
over potentially more uncomfortable muscle biopsy techniques
[87]. Importantly, in genetic disorders of early childhood, swift
and robust diagnostic and prognostic procedures will be crucial
for the reliable evaluation of new therapeutic strategies, such as
gene or stem cell therapy. Thus, biofluid-associated biomarkers
are excellent candidates for the implementation of liquid biopsy
procedures in the field of muscular dystrophy.
4.1. Advances in biofluid array technology
Antibody arrays (or forward-phase protein assays; FPPAs) are
mainly applied to quantify analytes that are present in com-
plex samples. Antibody arrays are an established proteomic
technology providing an exceptional methodology for various
Table 2. (Continued).
Species/Tissue Methods Key proteomic changes Reference
Mouse mdx-23 skeletal muscles IP, XL, LC-MS/MS Charcterization of β-dystroglycan and caveolin
subcomplexes in Dp427-deficient muscle
[44]
Mouse mdx-4cv hind limb muscles (microsomes) XL, SDS-PAGE, LC-MS/MS Increased oligomerization of myoferlin, caveolin,
vimentin and tubulin
[77]
Mouse mdx-4cv hind limb muscles following
treadmill exercise
2D-GE, MALDI-ToF MS Exercise-induced increase in fast troponin TnT and TnI,
myozenin, glycolytic enzymes
[78]
Mouse mdx-4cv skeletal muscles Lectin affinity agglutination of
sarcolemma, LC-MS/MS
Increased myoferlin, dysferlin and annexins; decreased
periaxin and myelin PO
[45]
Mouse mdx-4cv diaphragm LC-MS/MS Increased myosin-8 and vitronectin; decreased
parvalbumin and fatty acid binding protein FABP3
[30]
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applications, such as protein expression profiling and biomar-
ker discovery (diagnostics/prognostics/therapy selection/dis-
ease monitoring) in samples ranging from cells, tissues,
serum and conditioned media to more novel biofluids such
as nipple aspirate fluid and tears [88]. An antibody array is
a multiplex immunoassay that can utilise the ELISA (enzyme-
linked immunosorbent assay) sandwich antibody pair princi-
ple, which allows researchers to detect potentially several
hundred proteins within a single analysis. The antibodies are
individually deposited in an ordered pattern, with each anti-
body printed as replicates to improve confidence in subse-
quent results. Positive and negative controls are included to
maximize data reliability. Bead-based arrays of the Luminex
type rely on colour-coded beads, pre-coated with analyte-
specific capture antibody for the molecule of interest, with
each antigen then being identified based on bead colour [89].
The typical workflow of an antibody microarray involves
the choice of an appropriate antibody array platform (solid
or bead), blocking of non-specific reactive groups, selection of
suitable samples containing soluble proteins of interest and
incubation with the antibody array, where targeted proteins
from the sample are captured by the antibodies. The resulting
binding events are reported precisely by fluorescent labelling
of the sample or by the addition of a secondary detection
reagent. Most of the antibody arrays can achieve pg/ml
detection for specific antigens, similar to single ELISA detec-
tion methodology [90]. However, to overcome potential cross-
reactivity and target protein abundance issues and concerns
at detecting low/high abundant target proteins on the same
array, more specialised arrays can be developed to mitigate for
these trepidations. Current off-the-shelf antibody array panels
include those specifically developed to detect and quantitate
various cytokines, chemokines, adipokines, growth factors,
proteases, soluble receptors and adhesion molecules. The cus-
tom option offers researchers the flexibility to design tailored
panels to meet niche demands where novel biomarkers or
marker molecules harbouring specific post-translation modifi-
cations need to be included as part of an antibody array panel.
Antibody array technology has proven to be a successful
approach for identifying urgently needed biomarkers for mus-
cular dystrophies. Using an antibody bead array platform with
384 antibodies, eleven proteins associated with muscular dys-
trophy were identified from the analysis of both serum and
plasma patient samples [91]. Four proteins were established as
having increased abundance levels in blood from Duchenne
and Becker’s muscular dystrophy patients compared to control
groups, i.e. carbonic anhydrase CA3, myosin light chain MYL3,
mitochondrial malate dehydrogenase MDH2 and electron
transfer flavoprotein ETFA. If confirmed by longitudinal stu-
dies, these new protein signatures could then be used to
Figure 5. Overview of the wider dystrophin complexome and sarcolemmal protein markers as revealed by mass spectrometry-based proteomics. Shown are the
various protein species that were shown to be linked to the wider sarcolemmal protein network and its associated subcellular systems, including the extracellular
matrix, the cytoskeletal network, the plasmalemma, the transverse tubules and the sarcoplasmic reticulum.
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monitor disease progression and facilitate clinical manage-
ment decisions for dystrophic patients. Ho and co-workers
[92] demonstrated how a Luminex mouse 38-plex kit was
used to determine if mdx/mTRG2 mice may have developed
a peripheral inflammatory cytokine signature following sys-
temic delivery of micro-dystrophin vectors, an investigational
therapy involving systemic gene replacement to introduce
a functional dystrophin gene to skeletal and cardiac muscles.
Proteomic findings indicated an overall decrease in abun-
dance levels of IFN-γ, TNF-α, IL-6, and IL-17A within the vector-
treated group as compared with the vehicle group, however
these results were not statistically significant.
Lysate arrays (or reverse phase protein arrays; RPPAs) repre-
sent an innovative technology that combines high throughput
analysis with minimal sample consumption [93]. Small
amounts (low ng range) of protein (lysates from cells/tissue)
are printed onto nitrocellulose or glass slides. Proteins of
interest are then quantified using highly specific primary anti-
bodies, with slides potentially containing hundreds of indivi-
dual samples, with a specific pattern for each sample
containing serial dilutions and replicates. Escher et al. [94]
demonstrated how powerful RPPA approaches are when eval-
uating changes in protein expression between healthy and
diseased muscle tissue, as well as cultured primary myotubes.
This study established that the differential diagnosis of mus-
cular dystrophies using RPPAs in combination with a set of
diagnostic antibodies is a worthwhile strategy, as exemplified
by increased sarcoglycan signals in limb-girdle muscular dys-
trophy of type LGMD2A as compared to controls.
4.2. Novel biofluid markers of dystrophinopathy
Several proteomic studies have characterized blood, urine and
saliva samples for the establishment of novel biofluid-based bio-
markers of dystrophinopathy. Many complex biological fluids are
readily available and can be easily collected for systematic proteo-
mic analysis [87]. If specific proteoforms are passively released or
actively secreted in response to pathophysiological processes,
these types of proteins are an excellent startingpoint for designing
new diagnostic assays, establish superior prognostic tests and
develop more reliable techniques for the continued monitoring
of novel therapeutic approaches to treat X-linkedmuscular dystro-
phy. Table 4 lists biomarker candidates that have been identified
through the systematic screening of suitable biofluids [91,95–113].
Importantly, glucocorticoids are routinely used for treating chronic
inflammatory conditions, including dystrophinopathies, making
biofluid proteomics an essential part of the establishment of bio-
markers of the anti-inflammatory response to this category of
drugs [114]. Systematic investigations with a focus on serum bio-
markers for chronic corticosteroid treatment revealed new candi-
date pharmacodynamic markers for evaluating anti-inflammatory
drug efficacy, including leptin and matrix metalloproteinase
MMP3 [115].
Proteomic screening studies have used samples from estab-
lished animalmodels ofmuscular dystrophy, as well as blood and
urine specimens from Duchenne patients. The identification of
proteomic biomarker candidates in the blood included the con-
firmation of general indicators of muscle damage, such as crea-
tine kinase, myoglobin and glycolytic enzymes, as well as novel
proteins involved in metabolism, the extracellular matrix and the
sarcomeric structures [91, 95–98,100–110]. Significant changes
included fibronectin, fibrinogen, carbonic anhydrase CA3, myo-
sin light chain MLC3, mitochondrial malate dehydrogenase, titin,
myomesin, troponin TnI, calcium/calmodulin-dependent protein
kinases, fatty acid binding proteins and the inflammation-
induced plasma protein haptoglobin. In addition, leptin was
identified as a new biomarker candidate and is potentially linked
to the metabolic syndrome in Duchenne patients [116,117].
Interestingly, urine samples from Duchenne patients con-
tained increased levels of uromodulin, which is exclusively
synthesised in renal tissue and presents the most abundant
kidney protein in urine, and N- and C-terminal fragments of the
giant muscle protein titin [99]. Titin is a stabilising half-sarcomere
spanning component of the acto-myosin apparatus in skeletal
muscle fibres [7] and the appearance of titin fragments in urine
indicates the pathological release of this structural protein into
the circulatory system due to muscular dystrophy. The recent
mass spectrometric survey of whole saliva from the mdx-4cv
Table 3. Proteomic profiling of non-skeletal muscle tissues in association with X-linked muscular dystrophy. Listed are major proteomic studies with a focus
on the comparative mass spectrometric analysis of non-skeletal muscle tissues, including heart, liver, kidney and brain specimens. Abbreviations used: LC-MS/MS,
liquid chromatography tandem mass spectrometry; DIGE, difference in-gel electrophoresis; IP, immunoprecipitation; SILAM, stable isotope labeling in mammals.
Species/Tissue Methods Key proteomic changes Reference
Mouse mdx-23 heart 2D-DIGE, LC-MS/MS Differential changes in mitochondrial and metabolic proteins [79]
Mouse mdx-23 heart 2D-DIGE, LC-MS/MS Increased lamin-A/C; decreased ATP synthase, fatty acid binding protein
FABP3 and adenylate kinase AK1
[80]
Mouse mdx-5cv heart IP using antibodies to
dystrophin, LC-MS/MS
Altered cardiac dystrophin interactions with syntrophin/dystrobrevin [38]
Mouse mdx-23 heart LC-MS/MS Cardiac-specific decrease in laminin, nidogen and annexin ANX6 [81]
Mouse mdx-4cv brain LC-MS/MS Increased glial fibrillary acidic protein, calretinin, annexin ANX5 and vimentin [82]
Mouse mdx-23 kidney following
antisense PMO treatment
SILAM mouse analysis PMO-related increase in glutamyl aminopeptidase and kidney marker meprin
MEP-1
[83]
Mouse mdx-4cv heart LC-MS/MS Increased periostin, asporin, lumican, cardiac-specific myosin light chain
kinase; decreased laminin and sarcalumenin
[84]
Mouse mdx-4cv liver LC-MS/MS Increased fatty acid binding protein FABP5, ferritin and calumenin; decreased
phospho-glycerate kinase and perilipin
[85]
Mouse mdx-4cv brain LC-MS/MS Secondary disturbances in fatty acid and carbohydrate metabolism [86]
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model of dystrophinopathy identified an increased concentra-
tion of kallikrein-1 and its related peptidases Klk1-b1, Klk1-b5 and
Klk-b22 [113]. Significantly higher levels of kallikrein-1 were also
found inmdx-4cv serum samples [110]. These altered concentra-
tions of kallikreins in biofluids are probably related to muscular
dystrophy-related changes in cellular signalling mechanisms, re-
modelling of the extracellular matrix and a modified immune
response. The successful proteomic screening of plasma, serum,
urine and saliva samples demonstrates the suitability of liquid
biopsy methods for the evaluation of body-wide changes in
dystrophinopathy.
Figure 6 provides an overview of proteomic biomarker
candidates that are associated with X-linked muscular dys-
trophy. The diagram lists (i) primary tissue markers of the
disintegration of the core dystrophin complex, (ii) protein
families that are secondarily affected in muscular dystrophy
and (iii) biofluid markers that are found in the circulatory
system due to passive protein leakage or active protein
release.
5. Expert opinion
Since many chronic disorders, such as diabetes, neurological
diseases, cardiovascular disorders or cancer trigger a variety of
relatively general pathophysiological alterations in the com-
position of the circulatory system, it is crucial to establish
a skeletal muscle disease-specific damage marker signature.
Often changes in the levels of hormones, cytokines, metabolic
enzymes or signalling proteins are not specific enough to
properly evaluate a specific neuromuscular pathology.
However, based on the systematic application of mass spec-
trometry-based proteomics in the field of muscular dystrophy
research, select dystrophin-associated proteins, a large num-
ber of indirectly affected tissue components and
a considerable array of biofluid-associated proteins can now
be used to develop novel and hopefully more reliable diag-
nostic and prognostic marker assays. It should also be possible
to exploit some newly established proteomic markers as ther-
apeutic targets to treat progressive fibre wasting in X-linked
muscular dystrophy.
Table 4. Proteomics of biofluid changes in association with X-linked muscular dystrophy. Listed are major proteomic studies with a focus on the comparative
mass spectrometric analysis of biofluids, including serum, urine and saliva. Abbreviations used: 2D-GE, two-dimensional gel electrophoresis; LC-MS/MS, liquid
chromatography tandem mass spectrometry; DMD, Duchenne muscular dystrophy; ELISA, enzyme-linked immunosorbent assay; MALDI ToF, matrix assisted laser
desorption/ionization time-of-flight; SILAC, stable isotope-labeled amino acids.
Species/Tissue Methods Key proteomic changes Reference
Mouse mdx-23 and mdx-3cv
serum
Magnetic beads affinity
purification, MALDI-ToF MS
Identification of differentiating N-terminal peptide of coagulation factor XIIIa [95]
Mouse mdx-23 plasma 2D-GE, LC-MS/MS Increased fibrinogen, epidermal growth factor 2 receptor and glutathione peroxidase
GPX3
[96]
Secretome of mouse mdx-23
myotubes
SILAC labelling, LC-MS/MS Enrichment of LAMP1/MLC-1 (lysosomal-associated membrane protein/myosin light
chain) – positive vesicles
[97]
Human DMD serum ProteoMiner beads enrichment,
LC-MS/MS, ELISA
Increased fibronectin levels [98]
Human DMD serum and
plasma
Large-scale screening with
antibody bead array platform
Increased carbonic anhydrase CA3, myosin light chain MLC3, mitochondrial malate
dehydrogenase MDH2, electron transfer flavoprotein ETFA
[91]
Human DMD and mouse
mdx-23 urine
Sample concentration, LC-MS
/MS
Increased uromodulin and N-/C-terminal titin fragments, decreased cubulin [99]
Mouse mdx-23 and mdx-52
and human DMD serum
SILAC mouse analysis, LC-MS
/MS
Increased titin, myosin light chain MLC1/3, myomesin MYOM3, filamin-C, myoglobin [100]
Mouse mdx-23 urine SILAM mouse technology,
antisense PMO treatment
Increase in clusterin, differential changes in gamma-glutamyltranspeptidase GGT1 [83]
Human DMD and mouse
mdx-23 serum
Immuno-depletion, LC-MS/MS,
antisense PMO treatment
Increased myomesin MYOM3, pyruvate kinase, carbonic anhydrase CA3 [101]
Human DMD and mouse
mdx-23 serum
Aptamer-based SOMAscan
screening
Identification of troponin TnI, phosphglycerate mutase PGAM1, calcium/calmodulin-
dependent protein kinase CAMK2b and Cytochrome-c
[102]
Human DMD serum Aptamer-based SOMAscan
screening
Identification of troponin TnI, carbonic anhydrase CA3, myoglobin, fatty acid binding
protein FABP3
[103]
Human DMD serum 2D-HPLC, MALDI-ToF MS Identification of titin, calmodulin-like protein CALM-5 and carbonic anhydrase CA1 [104]
Human DMD serum SOMAscan screening, LC-MS/MS Overview of DMD serum biomarker candidates [105]
Mouse mdx-4cv serum Immuno-depletion, LC-MS/MS Increased levels of inflammation-induced plasma marker haptoglobin [106]
Mouse mdx-23 and
transgenic mdx-23 Fiona
serum
Aptamer-based SOMAscan
screening
Increased utrophin related identification of tumor necrosis factor receptor GITR,
myosin-binding protein C and heat shock protein Hsp60
[107]
Human DMD and mouse
mdx-23 serum
Immuno affinity purification, LC-
MS/MS
Decreased myostatin in DMD and other neuromuscular disorders [108]
Human DMD serum Aptamer-based SOMAscan
screening
Identification of troponin TnI, carbonic anhydrase CA3, myoglobin and fatty acid
binding protein FABP3
[109]
Mouse mdx-4cv saliva and
serum
Immuno-depletion, LC-MS/MS Identification of differential saliva/serum markers [110]
Human DMD serum Aptamer-based SOMAscan
screening
Identification of calcium/calmodulin-dependent protein kinases CAMK2a and
CAMK2b, carbonic anhydrase CA3 and fatty acid binding protein FABP3
[111]
Mouse dKO-Hom serum LC-MS/MS Dystrophin/utrophin double-KO related decrease in haptoglopin and increase in
peroxiredoxin-2
[112]
Mouse mdx-4cv saliva LC-MS/MS Increased kallikrein Klk-1 and Klk1-related peptidases b1, b5 and b22 [113]
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Especially liquid biopsy procedures that use independently
verified protein biomarkers should be helpful to improve the
diagnosis and therapy monitoring of X-linked muscular dystro-
phy. The recent identification of additional muscular dystrophy-
specific enzymes in easily sourced biofluids, such as blood,
urine and saliva, will be extremely useful for clinical applications
that are based on the dependable measurement and analysis of
disease progression and therapeutic response. Serum-
associated fibronectin, carbonic anhydrase, myosin light chain,
myomesin, troponin, fatty acid binding proteins and haptoglo-
bin, as well as titin fragments in urine and saliva kallikrein have
great potential to be useful biomarkers of dystrophinopathy. In
contrast to the high costs, invasive character and clinical neces-
sity of full asepsis of muscle biopsy procedures, non-invasive
liquid biopsy procedures have the advantage of being more
cost-effective, quicker and can be applied in a repeated manner
for optimum therapy monitoring.
Over the next few years, it will be critical to verify the
general biomedical suitability of the newly identified pro-
teomic marker molecules that are associated with X-linked
muscular dystrophy. In contrast to biofluid analyses from
patients, the proteomic identification of tissue-associated
marker molecules has almost exclusively been carried out
with animal models of X-linked muscular dystrophy. Hence,
there is an urgent need to extent proteomic studies of
dystrophic skeletal muscle fibres to human tissue samples.
For the translation of biomarker usage as a routine diag-
nostic tool in the clinical setting, potential problems with
inter-individual differences in large patient cohorts have to
be evaluated. Although it is difficult to obtain large num-
bers and quantities of muscle biopsy material from paedia-
tric patients, it should be possible to perform comparative
profiling studies with restricted amounts of human tissue by
using advanced and highly sensitive mass spectrometric
approaches. Both, miniaturized gel- and/or liquid chromato-
graphy-based procedures should be suitable for such ana-
lyses. Proteome-wide changes in newly identified
biomarkers in tissues versus biofluids should then be patho-
biochemically correlated. Subsequently new biomarker sig-
natures have to be established in clinical laboratory practice
for the superior evaluation of patient health status and the
degree of skeletal muscular damage and contractile weak-
ness. Ideally, longitudinal studies would be used to deter-
mine the robustness of new diagnostic markers and
evaluate the modifying effects of routinely applied drug
regimes, including pharmacological agents used in the sup-
portive treatment of Duchenne patients, i.e. corticosteroids,
beta blockers and angiotensin-converting-enzyme inhibitor.
Figure 6. Schematic presentation of proteomic biomarker candidates that are associated with dystrophinopathy. The diagram lists primary tissue-associated markers
of the sarcolemmal dystrophin-glycoprotein complex, protein families that are secondarily affected during chronic fibre wasting and biofluid markers that are
passively leaked or actively released from dystrophic muscle tissue.
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In the long-term, simple dot blot methods, standardized
enzyme-linked immunosorbent assays, antibody arrays or
miniaturized immunoblotting techniques have to be devel-
oped for routine diagnostic procedures. These assay systems
should ideally test protein changes within a broad biomarker
signature, which covers complex alterations due to tissue
degeneration, reactive myofibrosis and sterile inflammation
in the affected skeletal musculature, as well as secondary
changes in the heart, liver, kidney and the central nervous
system. Testing of proteomic markers can also be combined
with non-proteinaceous molecules, such as extracellular
microRNAs, lipids and/or metabolites. Noteworthy, fatty sub-
stitution in dystrophic muscles and ectopic fat depots in
other organs due to muscular dystrophy has not been exten-
sively researched by modern large-scale methodologies.
Since alterations in a number of fatty acid binding protein
isoforms have been described in various tissues and bio-
fluids, it is of considerable interest to better understand
abnormal fatty acid metabolism. The systematic proteomic
screening of the liver, kidney and pancreas in combination
with blood and urine samples could improve our under-
standing of secondary metabolic dysfunctions in dystrophi-
nopathy. The standardization of biomarker assays will be
especially crucial for the testing of new therapeutic
approaches in the field of muscular dystrophy, such as stem
cell therapy, utrophin substitution, steroid applications, stop
codon read-through therapy, exon-skipping and CRISPR/
Cas9-related genome editing. Ideally new liquid biopsy-
based biomarker assays will be combined with conventional
examination methods, such as strength tests and skeletal
muscle imaging, for the improved diagnosis and prognosis
of Duchenne muscular dystrophy.
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